

Chemical Synthesis of Fucosylated Chondroitin Sulfate Tetrasaccharide with Fucosyl Branch at the 6-OH of GalNAc Residue

Changlun Lv¹, Xiaona Li¹, Guoqing Yang¹, Haijiao Chen¹, Chunxia Li^{1,2 *}

1.Key Laboratory of Marine Drugs, Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China

2. Laboratory of Marine Drugs and Bioproducts of Qingdao Pilot National Laboratory for Marine Science and Technology, Qingdao 266237, China)

* Corresponding author. Email address: lchunxia@ouc.edu.cn (Chunxia Li).

Contents of Supporting Information

Experimental Procedures of compound 19 and 20	S3
Figure S1. ^1H NMR and ^{13}C NMR spectrum of compound 19	S5
Figure S2. ^1H NMR and ^{13}C NMR spectrum of compound 20	S6
Figure S3. ^1H NMR and ^{13}C NMR spectrum of compound 21	S7
Figure S4. ^1H NMR and ^{13}C NMR spectrum of compound 22	S8
Figure S5. ^1H NMR and ^{13}C NMR spectrum of compound 24	S9
Figure S6. ^1H NMR and ^{13}C NMR spectrum of compound 25	S10
Figure S7. ^1H NMR and ^{13}C NMR spectrum of compound 26	S11
Figure S8. ^1H NMR and ^{13}C NMR spectrum of compound 27	S12
Figure S9. ^1H NMR and ^{13}C NMR spectrum of compound 29	S13
Figure S10. ^1H NMR and ^{13}C NMR spectrum of compound 30	S14
Figure S11. ^1H NMR and ^{13}C NMR spectrum of compound 34	S15
Figure S12. ^1H NMR and ^{13}C NMR spectrum of compound 35	S16
Figure S13. ^1H NMR and ^{13}C NMR spectrum of compound 36	S17
Figure S14. ^1H NMR and ^{13}C NMR spectrum of compound 37	S18
Figure S15. ^1H NMR and ^{13}C NMR spectrum of compound 38	S19
Figure S16. ^1H NMR and ^{13}C NMR spectrum of compound FCS-1	S20
Figure S17. ^1H NMR and ^{13}C NMR spectrum of compound FCS-2	S21

Experimental Procedures

1-Ethylthio-3-O-benzyl- β -L-fucopyranoside (**19**)

To a solution of **16**^[5] (100 mg, 0.48 mmol) in dry toluene (5 mL) was added Bu₂SnO (240 mg, 0.96 mmol) under nitrogen atmosphere. The reaction mixture was heated under reflux for 5 h, then concentrated *in vacuo*. The obtained residue was dissolved in DMF (3 mL), and CsF (146 mg, 0.96 mmol), BnBr (86.2 μ L, 0.72 mmol) were added and stirred at room temperature overnight. The reaction mixture was filtered through celite, extracted with DCM and washed with water and brine. The organic phase was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (DCM/CH₃OH=30:1, v/v) to afford white solid compound **19** (127.6 mg, 89.1%). *R*_f = 0.85 (DCM/CH₃OH=10:1, v/v). ¹H NMR (500 MHz, CDCl₃): δ 7.38-7.26 (m, 5H), 4.76 (s, 2H), 4.26 (d, *J* = 9.7 Hz, 1H), 3.81-3.76 (m, 2H), 3.59 (q, *J* = 6.1 Hz, 1H), 3.44-3.42 (dd, *J* = 8.7, 2.3 Hz, 1H), 2.79-2.68 (m, 2H), 2.47 (s, 1H), 2.34 (s, 1H), 1.34 (d, *J* = 6.2 Hz, 3H), 1.30 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 137.9, 128.7, 128.2, 128.0, 86.0, 81.8, 74.7, 72.2, 69.6, 69.3, 24.1, 16.9, 15.4. HRMS (ESI) *m/z* calcd for C₁₅H₂₃O₄S [M+H]⁺ 299.1317, found 299.1312.

1-Ethylthio-2,4-di-O-(2-naphthylmethyl)-3-O-benzyl- β -L-fucopyranoside (**20**)

To a solution of **19** (76 mg, 0.26 mmol) in dry DMF (2 mL) were added NaH (60% in mineral oil, 20 mg, 0.51 mmol) and NapBr (226 mg, 1.02 mmol) at 0 °C

under nitrogen atmosphere. After being warmed to room temperature, the mixture was stirred 5 h. The reaction was quenched with saturated NH_4Cl and then extracted with DCM. The organic phase was washed with water and brine, dried with anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (PE/EtOAc=10:1, v/v) to afford white solid compound **20** (96 mg, 65%), R_f =0.78 (PE/EtOAc=2:1, v/v). ^1H NMR (400 MHz, CDCl_3) δ 7.87-7.74 (m, 8H, Ar-H), 7.60-7.43 (m, 6H, Ar-H), 7.42-7.28 (m, 5H, Ar-H), 7.26 (s, 1H, Ar-H), 5.15 (d, J = 11.9 Hz, 1H, Nap- CH_2), 5.08 (d, J = 10.4 Hz, 1H, Nap- CH_2), 4.98 (d, J = 10.5 Hz, 1H, Nap- CH_2), 4.90 (d, J = 12.0 Hz, 1H, Nap- CH_2), 4.85-4.75 (m, 2H, Ph CH_2), 4.45 (d, J = 9.6 Hz, 1H, H -1), 3.93 (t, J = 9.4 Hz, 1H, H -2), 3.68 (d, J = 2.3 Hz, 1H, H -4), 3.62 (dd, J = 9.3, 2.9 Hz, 1H, H -3), 3.51 (q, J = 6.2 Hz, 1H, H -5), 2.88-2.68 (m, 2H, SCH_2CH_3), 1.32 (t, J = 7.4 Hz, 3H, SCH_2CH_3), 1.24 (d, J = 6.4 Hz, 3H, H -6). ^{13}C NMR (100 MHz, CDCl_3): δ 138.7, 136.3, 136.1, 133.5, 133.3, 133.2, 133.1, 128.6, 128.1, 128.0, 127.8, 127.8, 127.7, 127.2, 127.0, 126.7, 126.6, 126.1, 126.0, 125.9, 85.2(C-1), 84.7(C-3), 78.6(C-2), 76.5(C-4), 75.9(Nap- CH_2), 74.7(C-5), 74.7(Nap- CH_2), 73.1(Ph- CH_2), 24.9(SCH_2CH_3), 17.5(C-6), 15.2(SCH_2CH_3). HRMS (ESI) m/z calcd for $\text{C}_{37}\text{H}_{42}\text{O}_4\text{NS}$ $[\text{M}+\text{NH}_4]^+$ 596.2829, found 596.2825.





Figure S1. ^1H NMR and ^{13}C NMR spectrum of compound **19**.






Figure S4. ^1H NMR and ^{13}C NMR spectrum of compound 22.




Figure S6. ¹H NMR and ¹³C NMR spectrum of compound **25**.




Figure S7. ¹H NMR and ¹³C NMR spectrum of compound **26**.




Figure S8. ¹H NMR and ¹³C NMR spectrum of compound 27.




Figure S9. ¹H NMR and ¹³C NMR spectrum of compound **29**.




Figure S14. ¹H NMR and ¹³C NMR spectrum of compound 37.




Figure S15. ^1H NMR and ^{13}C NMR spectrum of compound **38**.




Figure S16. ^1H NMR and ^{13}C NMR spectrum of compound **FCS-1**.




Figure S17. ¹H NMR and ¹³C NMR spectrum of compound FCS-2.